Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04830592
Title A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck (MOAT)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors PsiOxus Therapeutics Ltd
Indications

oropharynx cancer

laryngeal squamous cell carcinoma

head and neck squamous cell carcinoma

hypopharynx cancer

oral cavity cancer

Therapies

NG-641

NG-641 + Pembrolizumab

Age Groups: senior | adult
Covered Countries


No variant requirements are available.